Abstract | BACKGROUND/AIM: PATIENTS AND METHODS: Twelve patients with HCC with IHD were divided into two groups: HAIC group (n=6) underwent hepatectomy followed by HAIC; and the non-HAIC group (n=6) underwent hepatectomy alone. HAIC with cisplatin and 5-fluorouracil was started within a month and was continued for a month: Results: At the first local ablation, tumors close to the major portal vein and insufficient ablation were recognized in eight (67.7%) and six (58.3%) of the patients, respectively. In the HAIC group, the 1-, 3-, and 5-year disease-free and overall survival rates were 50.0%, 16.7%, and 16.7%, and 83.3%, 83.3% and 62.5%, respectively. Three patients in the HAIC group remain alive after 10 years of follow-up. CONCLUSION: Hepatic resection with short-term postoperative HAIC may provide excellent outcomes in patients with HCC and IHD.
|
Authors | Kunitaka Kuramoto, Toru Beppu, Hidetoshi Nitta, Katsunori Imai, Toshiro Masuda, Tatsunori Miyata, Yuki Koga, Yuki Kitano, Takayoshi Kaida, Shigeki Nakagawa, Hirohisa Okabe, Hiromitsu Hayashi, Daisuke Hashimoto, Yo-Ichi Yamashita, Akira Chikamoto, Ken Kikuchi, Hideo Baba |
Journal | Anticancer research
(Anticancer Res)
Vol. 38
Issue 1
Pg. 525-531
(01 2018)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 29277819
(Publication Type: Journal Article)
|
Copyright | Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Antimetabolites, Antineoplastic
- Cisplatin
- Fluorouracil
|
Topics |
- Aged
- Antimetabolites, Antineoplastic
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Hepatocellular
(drug therapy, pathology, surgery)
- Cisplatin
(therapeutic use)
- Combined Modality Therapy
(methods)
- Disease-Free Survival
- Female
- Fluorouracil
(therapeutic use)
- Hepatectomy
(methods)
- Hepatic Artery
- Humans
- Infusions, Intra-Arterial
- Liver
(pathology)
- Liver Neoplasms
(drug therapy, pathology, surgery)
- Male
- Middle Aged
|